BUZZ-Preview: UnitedHealth Group is expected to achieve a 42% year-on-year surge in profits
路透社2026/10/12 18:26October 12 - ** UnitedHealth Group (UNH.N) shares fell 0.7%, closing at $376.70 on Monday. The company will announce its third quarter financial results before the market opens on Tuesday.
** According to data from the London Stock Exchange Group (LSEG), the health insurance company is expected to report adjusted earnings per share (EPS) of $4.14, up 41.8% year-on-year, and revenue of $111.4 billion, compared to $113.16 billion in the same period last year.
** In the past eight quarters, UNH’s earnings per share have met or exceeded market expectations in six of them.
** On July 15, due to effective medical cost management, the company not only (link) beat quarterly earnings expectations but also raised its profit forecast for 2026.
** Of the 29 analysts covering UNH, 23 give a “strong buy” or “buy” rating, while the remaining six recommend “hold.”
** The median target price of $483.82 has increased by 12% compared to three months ago.
** Including Monday’s gains, UNH’s share price has risen by about 14% so far this year, while the Dow Jones Industrial Average has increased by about 8% in the same period .DJI
(For the convenience of non-English speakers, Reuters has automatically translated this report into several other languages. As automated translations may contain errors or lack proper context, Reuters does not guarantee the accuracy of this automated text and provides it solely for readers’ convenience. Reuters accepts no responsibility for any harm or loss arising from the use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Kroger (KR.US) faces the largest layoffs in 143 years: cutting one-third of positions, more than 3,000 employees to be let go
Kroger has laid off 3,000 employees, accounting for more than one-third of its total workforce, marking the largest layoff in its 143-year history. The resources saved will be redirected towards price reductions and frontline operations.
RBA Minutes: Case for rates to act promptly to keep inflation expectations anchored